Shares of Acadia Pharmaceuticals (NASDAQ:ACAD) traded today at $8.70, breaking its 52-week high. So far today approximately 18.6 million shares have been exchanged, as compared to an average 30-day volume of 1.3 million shares.
In the past 52 weeks, Acadia Pharmaceuticals share prices have been bracketed by a low of $1.29 and a high of $8.70 and are now at $8.67, 572% above that low price. Over the last five market days, the 200-day moving average (MA) has gone up 2.3% while the 50-day MA has advanced 1.6%.
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company is currently working on the treatment of induced dysfunction in Parkinson's disease ,schizophrenia, neuropathic pain and glaucoma.
Acadia Pharmaceuticals (NASDAQ:ACAD) is currently priced 3.1% above its average consensus analyst price target of $8.40. The stock should find initial support at its 50-day moving average (MA) of $6.02 and further support at its 200-day MA of $3.35.